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SUMMARY
The success of childhood vaccination against hepatitis B relies on persistence of immunity into
adolescence and adulthood. In 2000, two hexavalent vaccines with a hepatitis B component
(Hexavac1, Infanrix hexa1) were introduced in Germany. Hexavac was withdrawn in 2005
amidst concerns about its long-term hepatitis B protection. We compared hepatitis B surface
antibody (anti-HBs) levels in children fully vaccinated with Hexavac or Infanrix hexa (n=477) in
a secondary data analysis of a large cross-sectional health survey in Germany. On average 2.4
years after vaccination, 25.3% of Hexavac vaccinees had anti-HBs levels <10 mIU/ml (95% CI
19.0–32.8) compared to 4.7% of Infanrix hexa vaccinees (95% CI 2.4–8.9). These findings
suggest that short-term hepatitis B immunogenicity in Hexavac vaccinees may also be weaker.
Further studies are warranted to assess whether Hexavac vaccinees should be re-vaccinated or
receive a booster vaccination before these birth cohorts reach adolescence.
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INTRODUCTION
Vaccination against hepatitis B in early childhood is
the most effective way of preventing spread of infec-
tion. According to published data, available vaccines
induce a protective antibody response to hepatitis B
surface antigen (anti-HBs) in about 95% of vaccinees
and confer long-lasting protection against hepatitis B
infection in immunocompetent individuals [1–8].
The magnitude of the anti-HBs response is largely
influenced by vaccine regimen, body mass, site and
route of injection, immunosuppression, and age
[9–12]. A peak anti-HBs concentration o10 milli
international units per millilitre (mIU/ml) measured
1 month after completion of primary vaccination
course is considered to provide long-term immunity
[5]. Even in individuals whose anti-HBs concentration
decreases to lower or undetectable levels, protection
against disease is likely to persist due to the mainten-
ance of HBsAg specific immunological memory
[13–16]. Nonetheless, it has not been firmly estab-
lished whether booster vaccination is necessary and if
so, at what intervals [1–3, 6, 8, 17].
Germany, a country with a low endemicity for
hepatitis B, introduced national recommendations for
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universal hepatitis B vaccination of infants, children,
and adolescents in 1995. In 2000, two hexavalent vac-
cines, Hexavac1 (Sanofi Pasteur MSD), France and
Infanrix hexa1 (GlaxoSmithKline, Belgium), against
diphtheria, tetanus, pertussis, hepatitis B, polio and
Haemophilus influenzae type b were approved for use
in Germany. Both vaccines were licensed for either a
three- or a four-dose primary series. In Germany the
routine vaccination schedule for hexavalent vaccines
recommends four doses at ages of 2, 3, 4, and 11–14
months, with at least 6 months between the third
and fourth dose [18]. The recommendations made no
preference for either vaccine.
Hepatitis B vaccination coverage in Germany in-
creased markedly in conjunction with the availability
of hexavalent vaccines and data from the German
National Health Interview and Examination Survey
for Children and Adolescents (KiGGS) shows that
hexavalent vaccines practically replaced vaccination
with monovalent hepatitis B vaccinees during child-
hood [19, 20].
In 2005, the European Medicines Agency (EMEA)
suspended the marketing authorization for Hexavac
due to precautionary concerns about the long-term
persistence of immunogenicity of the hepatitis B com-
ponent of the vaccine [21, 22]. Additionally, there was
some evidence that Hexavac-vaccinated children who
achieved anti-HBs levels between 10 and 100 mIU/ml
post-primary vaccination had no or a lower response
to booster vaccinations with monovalent hepatitis B
vaccines given at age 7–9 years, compared to children
whose initial levels were >100 mIU/ml [22]. Hexavac
was licensed in Germany in late October 2000 and
between 2001 and the time of its suspension in
September 2005, 5.8 million doses of vaccine were
prescribed, corresponding to at least 1.5 million vac-
cinated children (IMS Health, written communi-
cation). Hexavac was also licensed in nine other
European countries as well as in 19 additional coun-
tries worldwide [21].
Current knowledge on the immunogenicity of
Hexavac and Infanrix hexa has largely been gained
from clinical trials [23–27]. Questions remain about
the short- and long-term hepatitis B immunogenicity
in children vaccinated with these hexavalent vaccines
during routine immunization. To investigate this, we
compared anti-HBs levels in children in Germany
fully vaccinated with either Hexavac or Infanrix
hexa between 2000 and 2005 using data from a large
cross-sectional survey. We also assessed factors as-
sociated with anti-HBs concentrations <10 mIU/ml.
METHODS
The German Health Survey for Children and
Adolescents (KiGGS)
A nationwide cross-sectional survey, KiGGS, was
conducted between 2003 and 2006 [28]. KiGGS was
based on a nationally representative sample of children
and adolescents aged 0–17 years with main residence
in Germany. Participants were enrolled in two steps:
first, 167 study locations (sample points) were chosen;
second, subjects were randomly selected from the of-
ficial resident registers in the 167 sample locations. A
total of 17 641 subjects (8656 girls, 8985 boys) par-
ticipated in the survey (response 66.6%). Analysis
of the non-responder questionnaires showed that the
collected data gave comprehensive and nationally
representative evidence on the health status of children
and adolescents. To ensure that estimates derived
from KiGGS were representative at the national level,
weights were applied in statistical analyses to correct
for regional differences in the distribution of age
structure, sex, and nationality, and to compensate for
oversampling of individuals from Eastern Germany
which was undertaken to achieve sufficient statistical
power.
Data on age, sex, anthropometric variables, chronic
diseases, socio-economic status, and a large number
of health indicators were collected through interviews
and self-completed questionnaires. A wide range of
blood and urine tests were performed. Vaccination
status was extracted from hand-held vaccination
cards. A detailed description of the sampling method
has been published elsewhere [28, 29].
Hepatitis B testing
Laboratory tests for anti-HBs and antibodies to
hepatitis B core antigen (anti-HBc) were performed in
the majority of children aged 3–17 years (88%).
However, the proportion of children tested for anti-
HBs and anti-HBc was smaller in the younger age
groups due to more frequent refusals or blood sam-
pling failures. Anti-HBs and anti-HBc were deter-
mined by electrochemiluminescence immunoassay
(ECLIA, Roche Diagnostics, Switzerland) using auto-
matic ELECSYS 2010 Analyzer. Only samples which
were anti-HBc positive were tested for hepatitis B
surface antigen (HBsAg). Anti-HBs concentrationwas
determined quantitatively in the range 2–1000 mIU/
ml. Levels <2 mIU/ml were classified as undetect-
able, whereas concentrations>1000 mIU/ml were not
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further diluted. Tests for anti-HBc and HBsAg were
qualitative. Details of the laboratory methods have
previously been published [30].
Selection of subjects vaccinated with hexavalent
vaccines – subgroup analysis
For the purpose of this study, we selected a subset
of children from KiGGS. We included only children
who fulfilled the following four criteria : (i) previous
vaccination either with only four doses of Hexavac
or only four doses of Infanrix hexa; (ii) complete
and original vaccination card available ; (iii) at least
5 months between the third and fourth vaccination
dose, and (iv) results of anti-HBs and anti-HBc testing
available. Children who were positive for anti-HBc
or HBsAg, or who had been passively or actively im-
munized at birth were excluded from our dataset. For
the selected subgroup we extracted the following from
the KiGGS database: data on age, sex, birth weight,
results of anti-HBs testing, brand and dates of hexa-
valent vaccination, information on diseases whichmay
impair immunity, and concomitant administration of
other available childhood vaccines [measles, mumps
and rubella (MMR), pneumococcal, meningococcal,
varicella, influenza, hepatitis A, and tick-borne en-
cephalitis].
Statistical analysis
Wegrouped children according to anti-HBs levels (<2,
2 to<10, 10 to<100, 100 to<1000,o1000 mIU/ml)
and assessed differences in anti-HBs between Hexavac
and Infanrix hexa vaccinees using Pearson’s x2 test.
We performed weighted bivariate and multivariable
logistic regression analyses to identify factors as-
sociated with anti-HBs concentration <10 mIU/ml.
The weighted analyses were performed applying the
weights developed for KiGGS as described above.
For these analyses, we grouped subjects by vaccine
(four doses ofHexavac vs. four doses of Infanrix hexa),
anti-HBs concentration (<10 mIU/ml vs. o10 mIU/
ml), sex (male vs. female), birth weight [<2499 g
(underweight), o4500 g (overweight), o2500–4499 g
(normal)], concomitantly vaccinated [hexavalent vac-
cine administered alone vs. hexavalent vaccine ad-
ministered with other vaccine(s)], and age at first
vaccination dose (o6 months or <6 months). We in-
cluded bivariate predictors with P<0.25 in the mul-
tivariable model. Using a backward stepwise
elimination (P>0.05) in the multivariable analysis,
we removed variables not associated with anti-HBs
<10 mIU/ml. The prevalence of children with anti-
HBs <10 mIU/ml by time elapsed since completed
vaccination was estimated for each vaccine group
using multivariable logistic regression analysis. All
possible interaction terms were tested separately.
P values <0.05 were considered statistically signifi-




A total of 477 children fulfilled the inclusion criteria ;
227 were vaccinated with Infanrix hexa, and 250 with
Hexavac. The characteristics of the two vaccine
groups were similar in terms of sex, age, time since
completion of vaccination and birth weight (Table 1).
The only vaccines administered concomitantly with
Hexavac or Infanrix hexa were MMR (Hexavac,
n=12; Infanrix hexa, n=16) and pneumococcal vac-
cine (Hexavac, n=6; Infanrix hexa, n=1).
No child was known to have a disease associated
with impaired immunity, e.g. nephrotic syndrome,
Down’s syndrome, or human immunodeficiency virus
infection.
We excluded 201 children who had received four
doses of Hexavac or Infanrix hexa but did not fulfil
the other inclusion criteria. Of these, 183 had not been
tested for anti-HBs, 16 had received the fourth dose
<5 months after the third dose, and two were positive
for anti-HBc.
Excluded children were younger (median age 3.69
years) than those fulfilling all inclusion criteria (median
Table 1. Demographic, vaccination, and birth weight


















3.40 (1.88–5.27)* 3.39 (0.68–4.56)#
* n=222.
# n=246.
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age 3.90 years, Wilcoxon rank sum test 2.53; P=
0.011).
Prevalence of protective anti-HBs
The distribution of anti-HBs levels differed signifi-
cantly between the two vaccine groups 0.3–4.5 years
after the fourth dose (Table 2). For instance, in chil-
dren vaccinated with Hexavac, 25.3% (95% CI
19.0–32.8) had anti-HBs <10 mIU/ml compared to
4.7% (95% CI 2.4–8.9) of children vaccinated with
Infanrix hexa. A significantly larger proportion of
children vaccinated with Infanrix hexa (41.5%)
had very high anti-HBs levels (o1000 mIU/ml) com-
pared with Hexavac vaccinees (7.1%). This difference
was also pronounced in children who had completed
their vaccination f2 years previously (n=126). In
this group, 66.2% of Infanrix hexa vaccinees had an
anti-HBs levelo1000 mIU/ml compared to 11.9% of
Hexavac vaccinees (Pearson’s x2=36.3, P<0.001).
Bivariate logistic regression analysis
In the weighted bivariate logistic regression analysis,
vaccine type, birth weight, and years since completion
of vaccination were significantly associated with an
anti-HBs level <10 mIU/ml (P<0.01, Table 3), while
there was no association with sex, age at first vacci-
nation dose, and concomitant vaccinations (P>0.25).
Multivariable logistic regression analysis
In the multivariable logistic regression analysis, vac-
cine type, birth weight, and years since last vaccination
remained as independent risk factors for anti-HBs
<10 mIU/ml (Table 4). None of the interaction terms
significantly improved the model fit and were thus not
considered in the final model. The odds of having an
anti-HBs concentration <10 mIU/ml was eight times
higher in children vaccinated with Hexavac compared
to children vaccinated with Infanrix hexa and in-
creased by 1.8 for every additional year since com-
pletion of vaccination. Being underweight at birth
was also strongly associated with anti-HBs levels
<10 mIU/ml.
Persistence of anti-HBs by time since completed
vaccination
The prevalence of individuals with anti-HBs
<10 mIU/ml was significantly higher at any point
in time since vaccination in Hexavac vaccinees than in
Infanrix hexa vaccinees as modelled using logistic re-
gression (Fig. 1). For example 1 year post-vaccination,
the estimated prevalence of anti-HBs <10 mIU/ml
was 13.5% (95% CI 7.6–22.9) in children vaccinated
with Hexavac vs. 2.3% (95% CI 0.8–6.1) in children
vaccinated with Infanrix hexa. For children who com-
pleted vaccination 4 years earlier, an estimated 40.7%
(95% CI 25.9–57.3) of Hexavac vaccinees had anti-
HBs <10 mIU/ml compared to 9.2% (95% CI
4.5–17.9) of Infanrix hexa vaccinees (Fig. 1).
DISCUSSION
This study comparing anti-HBs levels in children
vaccinated only with Hexavac to those in children
vaccinated only with Infanrix hexa provides further
evidence on the immunogenicity of the hepatitis B
component of Hexavac. The significantly higher pro-
portion of children in our analysis with anti-HBs
levels both undetectable (12.9%) and <10 mIU/ml
(25.3%) in those vaccinated with Hexavac compared
to those vaccinated with Infanrix hexa (2.0% and
4.7%, respectively) suggests that short-term as well as
long-term immunogenicity in Hexavac vaccinees may
be weaker.
Several studies have shown that the persistence
of measurable antibody levels is related to peak
Table 2. Anti-HBs levels in Infanrix hexa1 and Hexavac1 vaccinees 0.3–4.5 years after fourth vaccine dose
Vaccine
Prevalence (%) of anti-HBs (mIU/ml) with binomial 95% CI
Undetectable 2 to <10 10 to <100 100 to <1000 o1000
Infanrix hexa
(n=227)
2.0 (0.8–4.5) 2.7 (1.1–6.5) 17.7 (12.8–24.0) 36.1 (28.3–44.8) 41.5 (33.8–49.7)
Hexavac
(n=250)
12.9 (8.9–18.3) 12.4 (8.4–17.9) 37.9 (31.1–45.3) 29.7 (23.4–36.8) 7.1 (4.2–11.8)
Pearson’s x2 (x2=106.718, P<0.001)
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anti-HBs levels after immunization [31–33]. The in-
creasingly higher prevalence of anti-HBs <10 mIU/ml
with time since completed vaccination in Hexavac
vaccinees compared to Infanrix hexa vaccinees as
suggested by our model is consistent with lower re-
ported anti-HBs levels post-primary vaccination for
Hexavac [27]. Similarly, the significantly higher pro-
portion of children vaccinated with Infanrix hexa
having anti-HBs levels o1000 mIU/ml within 2 years
of the last vaccination compared to those vaccinated
with Hexavac implies that Infanrix hexa vaccinees
might have responded with substantially higher anti-
HBs levels post-vaccination.
According to EMEA, the lower anti-HBs levels in
Hexavac vaccinees compared to Infanrix hexa vacci-
nees may be attributable to variability in the
Table 4. Results of the weighted multivariable logistic regression analysis, showing factors associated
with anti-HBs <10 mIU/ml (n=461)
Variable
Proportion (%) with
anti-HBs <10 mIU/ml Adj. POR* 95% CI# P value
Infanrix hexa1 (n=218) 4.7 1.00
Hexavac1 (n=243) 25.3 8.22 3.73–18.1 <0.001
Normal weight (n=433) 14.2 1.00
Underweight (n=28) 49.8 10.35 3.45–31.0 <0.001
Years since completed vaccination – 1.77 1.21–2.58 0.003
* Adjusted prevalence odds ratio.
# Binominal 95% confidence intervals.
Table 3. Results of weighted bivariate analysis of potential risk factors for anti-HBs <10 mIU/ml
Variable
Percent with anti-HBs
<10 mIU/ml POR* 95% CI# P value
Sex (n=477)
Male (n=239) 13.9 1.00
Female (n=238) 17.7 1.34 0.72–2.49 0.349
Vaccine (n=477)
Infanrix hexa1 (n=227) 4.7 1.00
Hexavac1 (n=250) 25.3 6.94 3.28–14.67 <0.001
Birth weight$ (n=461)
Normal weight (n=433) 14.2 1.00
Underweight· (n=28) 49.8 5.98 2.18–16.4 <0.001
Age first dose (n=477)
o6 months (n=23) 13.3 1.00
<6 months (n=454) 15.9 1.23 0.34–4.42 0.750
Concomitant MMR vaccination (n=477)
No (n=449) 17.2 1.00
Yes (n=26) 14.3 1.00 0.25–3.99 0.997
Concomitant pneumococcal vaccination (n=477)
No (n=470) 1.0
Yes (n=7) 28.6 1.74 0.29–10.48 0.540
Years since last vaccination (n=477) 1.69 1.17–2.43 0.005
MMR, Measles, mumps and rubella.
* Prevalence odds ratio.
# Binomial 95% confidence intervals.
$ Normal weight : 2500–4499 g, underweight :f2499 g (according to ICD-10 [48]). Data on birth weight was missing for nine
children. Seven children classified as overweight could not be included in the analysis as they all had anti-HBs >10 mIU/ml.
· Twenty-two were born preterm.
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production process of the hepatitis B component of
Hexavac [22]. The lower recombinant HBsAg content
in the Hexavac vaccine (5 mg HBsAg) compared to
that of the Infanrix hexa vaccine (10 mg HBsAg) may
also play a role ; however, an Italian study showed
that a high proportion of children (92.9%) vaccinated
in infancy with either 5 mg or 10 mg HBsAg had anti-
HBs levels o10 mIU/l 5 years after vaccination [34].
In that study, simultaneous vaccination with com-
bined diphtheria and tetanus vaccine or with polio
vaccine was associated with lower anti-HBs levels.
To what extent other differences in hexavalent vaccine
composition – particularly differences in the concen-
tration of the adjuvant aluminium hydroxide – might
be relevant, is not known. As the children in the two
vaccine groups were very similar in terms of a number
of factors which might influence response to vacci-
nation, the observed anti-HBs differences in our study
are unlikely to be due to differences between the
comparison groups.
The findings presented here are consistent with
previous reports. In particular, another recent Italian
study in children attending local health units found
that 31% of 113 Hexavac vaccinees had anti-HBs
<10 mIU/ml compared to only 4% of 129 Infanrix
hexa vaccinees 15 months post-primary vaccination
with three doses [35]. A clinical trial showed that
both the proportion of children with anti-HBs
o10 mIU/ml as well as geometric mean titres
(GMTs) were significantly higher in children vacci-
nated with three doses of Infanrix hexa compared
to three doses of Hexavac 1 month post-vaccination
[27]. A follow-up trial reported significantly higher
anti-HBs GMTs as well as seroprevalence rates at age
11–23 months in infants primed with Infanrix hexa in
the first study [26]. However, following a fourth
(booster) dose, the proportion of children with anti-
HBs o10 mIU/ml was similar in the two groups,
although GMTs remained significantly higher in
Infanrix hexa vaccinees. Finally, a vaccine trial in
Germany showed that >90% of children vaccinated
with four doses of Infanrix hexa had persistent pro-
tective anti-HBs levels 3.5–4 years after adminis-
tration of a fourth dose, thus supporting the findings
presented here [36].
Low birth weight was also strongly and indepen-
dently associated with anti-HBs levels <10 mIU/ml
in this study. Since a high proportion (79%) of the
children with low birth weight (n=28) were born
preterm, these findings are in keeping with other
studies which have shown decreased response to








































Model for Infanrix hexa
Model for Hexavac
Binomial 95% CI
Fig. 1. Estimated prevalence of Hexavac1 and Infanrix hexa1 vaccinees with anti-HBs <10 mIU/ml according to time since
completed vaccination as modelled by weighted logistic regression analysis. Open circles (Hexavac) and crosses (Infanrix
hexa) show the number of subjects with anti-HBs levels <10 mIU/ml in all subjects within each successive year after com-
pleted vaccination.
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We found no association between anti-HBs levels
<10 mIU/ml and concomitant vaccination with
MMR or pneumococcal vaccine ; however, the num-
ber of concomitantly vaccinated children was small.
Previous studies have reported lower geometric mean
anti-HBs levels with concomitant administration of
hexavalent vaccines and pneumococcal conjugate
vaccine [40, 41].
Our study has two major limitations. The first
limitation is inherent in the design of a cross-sectional
survey. Because data were only collected at a single
point in time for each participant, we could not assess
individual anti-HBs levels over time. Thus, we could
not firmly establish whether undetectable anti-HBs
levels were mainly due to primary vaccine failure, i.e.
non-response, or secondary vaccine failure, i.e. waning
immunity after seroconversion. Second, data on sev-
eral factors which might influence the response to vac-
cination, including non-chronic diseases, medication
(e.g. steroids), body weight at the time of vaccination
and vaccine administration route were unavailable in
this secondary data analysis. However, it appears
unlikely that children who received Hexavac would
differ from children vaccinated with Infanrix hexa in
these aspects.
EMEA’s suspension of Hexavac in 2005 was con-
sidered a precautionary measure and immediate
revaccination of children who completed primary
vaccination with Hexavac was not deemed necessary
[21]. However, the degree of short- and long-term
protection against hepatitis B infection in children
vaccinated with Hexavac remains unclear. Overall,
the clinical significance of anti-HBs <10 mIU/ml in
immunized individuals is not well understood. Studies
suggest that long-term persistence of high anti-HBs
levels, as well as immunological memory and the
degree of protection from infection are associated
with peak anti-HBs concentrations after vaccination
[31, 33, 42–44]. Several studies have shown that
healthy individuals with an anti-HBs concentration
<10 mIU/ml can be infected with hepatitis B, but
mostly retain protection against chronic infection
provided that they initially responded well to the vac-
cine [2, 3, 17, 33, 42, 43].
Most studies investigating long-term immunogen-
icity of hepatitis B vaccines and related immunological
memory followed up relatively small numbers of vac-
cinees in settings with intermediate or high hepatitis B
endemicity [5, 33, 42–45]. Some or all subjects in these
studies were either vaccinated with lower [43–45]
or higher [4, 33] doses of HBsAg-containing vaccines,
were vaccinated at birth [5, 43–45], or were vaccinated
with plasma-derived vaccines [33, 45]. Therefore, re-
sults of these studies are not directly applicable to
the German setting. However, some of these studies
showed a decrease in anti-HBs concentrations to
<10 mIU/ml over a period of up to 15 years in up to
60% of vaccinees [5, 33, 43, 45], with up to 50% un-
able to mount an anamnestic immune response [5, 43,
45]. Conversely, an Italian study found that 91.2%
of adolescents vaccinated with three doses of re-
combinant vaccine containing a high dose of HBsAg
(20 mg) retained anti-HBs-levels of>10 mIU/ml more
than 10 years later [4].
According to EMEA, there is some degree of un-
certainty as to whether Hexavac vaccinees with an
initial immune response of 10–100 mIU/ml anti-HBs
after primary vaccination can mount an anamnestic
response to a booster dose with monovalent hepatitis
B vaccines [22]. A study by Giambi et al. showed that
2/25 (8%) Hexavac vaccinees vs. 0/5 (0%) Infanrix
hexa vaccinees with anti-HBs levels <10 mIU/ml 15
months after receipt of three primary doses did not
attain anti-HBs levels >10 mIU/ml 1 month after a
booster dose with a monovalent hepatitis B vaccine ;
however, the difference was not statistically signifi-
cant [35].
Since hepatitis B booster vaccination is currently
not recommended for the general population in
Germany [18], the success of the childhood immuni-
zation policy relies on long-term immunity into ado-
lescence and beyond, when the risk of hepatitis B
infection increases with onset of sexual activity [46].
In countries with low endemicity, where natural ex-
posure to hepatitis B is limited, booster vaccinations
may be necessary to sustain immunity.
To establish whether Hexavac-vaccinated children
might require re-vaccination or a booster dose, studies
should be conducted to assess the ability of children
with low anti-HBs levels after completion of the pri-
mary series to mount an anamnestic response to
booster vaccination. Additional studies to assess the
long-term persistence of anti-HBs and investigation
of possible breakthrough infections in high-risk
populations should also be performed.
In Switzerland, administration of one dose of a
monovalent hepatitis B vaccine before the age of 8
years to children who had received four doses of
Hexavac was recommended following the suspension
of the vaccine [47]. The decision to implement a
similar strategy in Germany would largely depend on
the results of the above-mentioned studies.
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29. Hölling H, et al. The German Health Interview
and Examination Survey for Children and Adolescents
(KiGGS) : study management and conduct of field-
work [in German]. Bundesgesundheitsblatt Gesund-
heitsforschung Gesundheitsschutz 2007; 50 : 557–566.
30. Thierfelder W, et al. Biochemical measures in the
German Health Interview and Examination Survey
for Children and Adolescents (KiGGS). Bundes-
gesundheitsblatt Gesundheitsforschung Gesundheits-
schutz 2007; 50 : 757–770.
31. Jilg W, Schmidt M, Deinhardt F. Persistence of specific
antibodies after hepatitis B vaccination. Journal of
Hepatology 1988; 6 : 201–207.
32. van der Sande MA, et al. Long-term protection against
carriage of hepatitis B virus after infant vaccination.
Journal of Infectious Diseases 2006; 193 : 1528–1535.
33. McMahon BJ, et al.Antibody levels and protection after
hepatitis B vaccination : results of a 15-year follow-up.
Annals of Internal Medicine 2005; 142 : 333–341.
34. Faustini A, et al. Persistence of anti-HBs 5 years
after the introduction of routine infant and adolescent
vaccination in Italy. Vaccine 2001; 19 : 2812–2818.
35. Giambi C, et al. A cohort study to evaluate persistence
of hepatitis B immunogenicity after administration of
hexavalent vaccines. BMC Infectious Diseases 2008; 8 :
100.
36. Heininger U, et al. Booster immunization with a hexa-
valent diphtheria, tetanus, acellular pertussis, hepatitis
B, inactivated poliovirus vaccine and Haemophilus in-
fluenzae type b conjugate combination vaccine in the
second year of life : safety, immunogenicity and persist-
ence of antibody responses.Vaccine 2007; 25 : 1055–1063.
37. Kesler K, et al. Immune responses of prematurely born
infants to hepatitis B vaccination: results through three
years of age. Paediatric Infectious Disease Journal 1998;
17 : 116–119.
38. Losonsky GA, et al. Hepatitis B vaccination of prema-
ture infants : A reassessment of current recommenda-
tions for delayed immunization. Pediatrics 1999; 103 :
e14.
39. Lau YL, et al. Response of preterm infants to hepatitis
B vaccine. Journal of Pediatrics 1992; 121 : 962–965.
40. Olivier C, et al. Immunogenicity, reactogenicity, and
safety of a seven-valent pneumococcal conjugate
vaccine (PCV7) concurrently administered with a fully
liquid DTPa-IPV-HBV-Hib combination vaccine in
healthy infants. Vaccine 2008; 26 : 3142–3152.
41. Tichmann-Schumann I, et al. Immunogenicity and re-
actogenicity of four doses of diphtheria-tetanus three-
component acellular pertussis-hepatitis B-inactivated
polio virus Haemophilus influenzae type b vaccine
coadministered with 7-valent pneumococcal conjugate
vaccine. Pediatric Infectious Disease Journal 2005; 24 :
70–77.
42. Da Villa G, et al. Impact of hepatitis B vaccination in
a highly endemic area of south Italy and long-term
duration of anti-HBs antibody in two cohorts of vacci-
nated individuals. Vaccine 2007; 25 : 3133–3136.
43. Bialek SR, et al. Persistence of protection against
hepatitis B virus infection among adolescents vacci-
nated with recombinant hepatitis B vaccine beginning
at birth: a 15-year follow-up study. Pediatric Infectious
Disease Journal 2008; 27 : 881–885.
44. Whittle H, et al. Observational study of vaccine efficacy
14 years after trial of hepatitis B vaccination in
Gambian children. British Medical Journal 2002; 14 :
569–573.
45. Samandari T, et al.Differences in response to a hepatitis
B vaccine booster dose among Alaskan children and
adolescents vaccinated during infancy. Pediatrics 2007;
120 : e373–e381.
46. Walter J, et al. Hepatitis B and C risk factors in
Germany – results of the national surveillance [in
German]. Gesundheitswesen 2005; 67 : 441–447.
47. Swissmedic. Notification to health experts, 20
September 2005: Swissmedic suspends the license of the
Hexavac vaccine [in German]. Swissmedic Journal 2005;
9 : 678–679.
48. WHO. International Classification of Diseases (ICD),
2007. World Health Organization (http://apps.who.
int/classifications/apps/icd/icd10online/). Accessed 30
October 2009.
Low Hexavac hepatitis B immunogenicity 1629
